Form 8-K

8-K — Camp4 Therapeutics Corp

Accession: 0001628280-26-063740

Filed: 2026-09-28

Period: 2026-09-28

CIK: 0001736730

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — camp-20260928.htm (Primary)

EX-99.1 (a202609288-kexhibit991.htm)

EX-99.2 (a202609288-kexhibit992.htm)

GRAPHIC (a202609288-kexhibit991001.jpg)

GRAPHIC (a202609288-kexhibit991002.jpg)

GRAPHIC (a202609288-kexhibit991003.jpg)

GRAPHIC (a202609288-kexhibit991004.jpg)

GRAPHIC (a202609288-kexhibit991005.jpg)

GRAPHIC (a202609288-kexhibit991006.jpg)

GRAPHIC (a202609288-kexhibit991007.jpg)

GRAPHIC (a202609288-kexhibit991008.jpg)

GRAPHIC (a202609288-kexhibit991009.jpg)

GRAPHIC (a202609288-kexhibit991010.jpg)

GRAPHIC (a202609288-kexhibit991011.jpg)

GRAPHIC (a202609288-kexhibit991012.jpg)

GRAPHIC (a202609288-kexhibit991013.jpg)

GRAPHIC (a202609288-kexhibit991014.jpg)

GRAPHIC (a202609288-kexhibit991015.jpg)

GRAPHIC (a202609288-kexhibit991016.jpg)

GRAPHIC (a202609288-kexhibit991017.jpg)

GRAPHIC (a202609288-kexhibit991018.jpg)

GRAPHIC (a202609288-kexhibit991019.jpg)

GRAPHIC (a202609288-kexhibit991020.jpg)

GRAPHIC (a202609288-kexhibit991021.jpg)

GRAPHIC (a202609288-kexhibit991022.jpg)

GRAPHIC (a202609288-kexhibit991023.jpg)

GRAPHIC (a202609288-kexhibit991024.jpg)

GRAPHIC (a202609288-kexhibit991025.jpg)

GRAPHIC (a202609288-kexhibit991026.jpg)

GRAPHIC (a202609288-kexhibit991027.jpg)

GRAPHIC (a202609288-kexhibit991028.jpg)

GRAPHIC (a202609288-kexhibit991029.jpg)

GRAPHIC (a202609288-kexhibit991030.jpg)

GRAPHIC (a202609288-kexhibit992001.jpg)

GRAPHIC (a202609288-kexhibit992002.jpg)

GRAPHIC (a202609288-kexhibit992003.jpg)

GRAPHIC (a202609288-kexhibit992004.jpg)

GRAPHIC (a202609288-kexhibit992005.jpg)

GRAPHIC (a202609288-kexhibit992006.jpg)

GRAPHIC (a202609288-kexhibit992007.jpg)

GRAPHIC (a202609288-kexhibit992008.jpg)

GRAPHIC (a202609288-kexhibit992009.jpg)

GRAPHIC (a202609288-kexhibit992010.jpg)

GRAPHIC (a202609288-kexhibit992011.jpg)

GRAPHIC (a202609288-kexhibit992012.jpg)

GRAPHIC (a202609288-kexhibit992013.jpg)

GRAPHIC (a202609288-kexhibit992014.jpg)

GRAPHIC (a202609288-kexhibit992015.jpg)

GRAPHIC (a202609288-kexhibit992016.jpg)

GRAPHIC (a202609288-kexhibit992017.jpg)

GRAPHIC (a202609288-kexhibit992018.jpg)

GRAPHIC (a202609288-kexhibit992019.jpg)

GRAPHIC (a202609288-kexhibit992020.jpg)

GRAPHIC (a202609288-kexhibit992021.jpg)

GRAPHIC (a202609288-kexhibit992022.jpg)

GRAPHIC (a202609288-kexhibit992023.jpg)

GRAPHIC (a202609288-kexhibit992024.jpg)

GRAPHIC (a202609288-kexhibit992025.jpg)

GRAPHIC (a202609288-kexhibit992026.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: camp-20260928.htm · Sequence: 1

camp-20260928

0001736730false00017367302026-09-282026-09-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 28, 2026

CAMP4 THERAPEUTICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 001-42365 81-1152476

(State or other jurisdiction

of incorporation) (Commission

File Number) (IRS Employer

Identification No.)

100 Talcott Avenue

Suite 201

Watertown, MA

02472

(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number, including area code): (617) 651-8867

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading

Symbol(s) Name of each exchange

on which registered

Common Stock, par value $0.0001 per share CAMP The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On September 28, 2026, CAMP4 Therapeutics Corporation (the “Company”) held an Analyst Day meeting regarding its planned Phase 1/2 ASCEND clinical trial of CMP-002 in SYNGAP1-related disorder (the “ASCEND clinical trial”) and its pipeline of product candidates. A copy of the data presentation used in connection with the Analyst Day meeting is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In addition, on September 28, 2026, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at https://investors.camp4tx.com. This presentation is also furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this report is furnished pursuant to Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On September 28, 2026, the Company held an Analyst Day meeting at which it provided the following updates regarding the ASCEND clinical trial and the Company’s pipeline of product candidates.

ASCEND Clinical Trial

The ASCEND clinical trial is a Phase 1/2, randomized, double-blind, placebo-controlled, multiple ascending dose (“MAD”) study. Participants will be randomized 3:1 to receive intrathecal administration of CMP-002 or a sham procedure consisting of a pinprick. The clinical trial includes three MAD cohorts with a minimum of eight participants each, followed by an open-label extension study. The Company believes that the dose levels to be administered in each of the three cohorts are within the expected therapeutic range based on pharmacokinetic and pharmacodynamic modeling of its preclinical data. The primary goals of the clinical trial include demonstrating safety and tolerability, characterizing pharmacokinetics and selecting an optimal biological dose, and identifying relevant endpoints applicable to patients with SYNGAP-1-related disorder (“SRD”) for subsequent study of CMP-002.

The ASCEND clinical trial is designed to enroll participants aged 2 to less than 18 years with genetically confirmed SRD. Key inclusion criteria include a clinical diagnosis of SRD with genetic confirmation of a protein-truncating mutation in SYNGAP1 exons 5-19, a haploinsufficiency phenotype characterized by intellectual disability, inability to speak in full phrases, sleep disturbance, refractory epilepsy (defined as daily seizures despite at least one ongoing anti-seizure medication) and a prior trial of at least two anti-seizure medications, and a stable anti-seizure medication regimen prior to baseline. Key exclusion criteria include non-truncating SYNGAP1 variants (including missense variants, microdeletions, variants located in exons 1-4 or variants of uncertain significance), a history of central nervous system disease unrelated to SRD, spinal abnormalities or other conditions that would make intrathecal dosing unsafe, and clinically significant laboratory abnormalities.

The ASCEND clinical trial is designed to include a 28-day screening period, a baseline assessment period of at least four weeks, a treatment period during which three doses will be administered over approximately three months, and a post-treatment follow-up period with assessments at multiple timepoints over approximately six months. Total participant time in the clinical trial is expected to be approximately 10 months. The clinical trial includes daily seizure diary completion,

actigraphy monitoring, safety and side effect review and functional assessments across multiple domains throughout the clinical trial.

The ASCEND clinical trial will also assess exploratory endpoints across six key domains of SYNGAP1-related disorder: seizures, sleep, motor function and gait, communication, behavior, and development and cognition. Seizure and sleep assessments will include 24-hour video-electroencephalography (“EEG”), seizure diaries, the Seizure-Related Impact Assessment Scale, actigraphy, and the Children’s Sleep Habits Questionnaire. The clinical trial will utilize five validated scales to assess behavior, development, communication, and motor function: the Bayley Scales of Infant and Toddler Development, 4th Edition; the Vineland Adaptive Behavior Scales, 3rd Edition; the Aberrant Behavior Checklist, 2nd Edition; the Observer-Reported Communication Ability Measure; and the Gross Motor Function Measure. EEG-based measures will be utilized to assess multiple parameters.

The ASCEND clinical trial is planned to be conducted at more than 11 clinical trial sites across at least nine countries. Sites in the United Kingdom, Australia and Argentina have been approved by the relevant regulatory authorities. Sites in the European Union are under review by applicable regulatory and ethics authorities.

The Company expects to dose the first patient in the ASCEND clinical trial by the end of 2026. The Company is targeting a topline data readout from the ASCEND clinical trial in the first half of 2028.

Pipeline Updates

In addition, the Company provided an update on its broader pipeline of product candidates. The Company is advancing a preclinical program targeting SHANK3 for the treatment of Phelan-McDermid Syndrome, a neurodevelopmental disorder characterized by autism, developmental delay, intellectual disability, motor impairment and milestone regression, for which there are no approved disease-modifying treatments. The Company estimates that there are more than 45,000 patients with Phelan-McDermid Syndrome in the United States. The Company expects to designate a development candidate in the SHANK3 program in 2027. The Company also disclosed that it is evaluating programs for two additional early-stage haploinsufficient diseases of the central nervous system.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s strategy, goals, business plans and focus; preclinical data, clinical development plans and the anticipated timing of availability of clinical data and results from the Company’s planned ASCEND clinical trial; the Company’s regulatory interactions with the FDA; the Company’s expectations regarding the therapeutic potential of the Company’s product candidates; the Company’s estimates with respect to the addressable patient populations for its product candidates; the potential of the Company’s platform technology; and the Company’s expectations regarding its business prospects and results of operations. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “designed”, “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,”, “strive”, “target,” “will,” “would,” or the negative thereof and similar words and expressions. Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to the Company. Such statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions that may cause the Company’s actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. Such risks and uncertainties include, but are not limited to, the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development and risks related to additional

costs or delays in the development and commercialization of the Company’s current product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements; the Company’s ability to obtain regulatory approval to commercialize its product candidates; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates; and the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials, as was the risks detailed under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in the Company’s other filings with the U.S. Securities and Exchange Commission. The forward-looking statements in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update or revise any of the statements. The Company’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1

Analyst Day presentation, dated September 28, 2026.

99.2

Corporate presentation, dated September 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CAMP4 THERAPEUTICS CORPORATION

By: /s/ Josh Mandel-Brehm

Name: Josh Mandel-Brehm

Title: President and Chief Executive Officer

Date: September 28, 2026

EX-99.1

Filename: a202609288-kexhibit991.htm · Sequence: 2

a202609288-kexhibit991

EX-99.2

Filename: a202609288-kexhibit992.htm · Sequence: 3

a202609288-kexhibit992

GRAPHIC

Filename: a202609288-kexhibit991001.jpg · Sequence: 7

Binary file (102503 bytes)

Download a202609288-kexhibit991001.jpg

GRAPHIC

Filename: a202609288-kexhibit991002.jpg · Sequence: 8

Binary file (281940 bytes)

Download a202609288-kexhibit991002.jpg

GRAPHIC

Filename: a202609288-kexhibit991003.jpg · Sequence: 9

Binary file (108054 bytes)

Download a202609288-kexhibit991003.jpg

GRAPHIC

Filename: a202609288-kexhibit991004.jpg · Sequence: 10

Binary file (108846 bytes)

Download a202609288-kexhibit991004.jpg

GRAPHIC

Filename: a202609288-kexhibit991005.jpg · Sequence: 11

Binary file (76797 bytes)

Download a202609288-kexhibit991005.jpg

GRAPHIC

Filename: a202609288-kexhibit991006.jpg · Sequence: 12

Binary file (88704 bytes)

Download a202609288-kexhibit991006.jpg

GRAPHIC

Filename: a202609288-kexhibit991007.jpg · Sequence: 13

Binary file (119059 bytes)

Download a202609288-kexhibit991007.jpg

GRAPHIC

Filename: a202609288-kexhibit991008.jpg · Sequence: 14

Binary file (117272 bytes)

Download a202609288-kexhibit991008.jpg

GRAPHIC

Filename: a202609288-kexhibit991009.jpg · Sequence: 15

Binary file (114432 bytes)

Download a202609288-kexhibit991009.jpg

GRAPHIC

Filename: a202609288-kexhibit991010.jpg · Sequence: 16

Binary file (98213 bytes)

Download a202609288-kexhibit991010.jpg

GRAPHIC

Filename: a202609288-kexhibit991011.jpg · Sequence: 17

Binary file (112908 bytes)

Download a202609288-kexhibit991011.jpg

GRAPHIC

Filename: a202609288-kexhibit991012.jpg · Sequence: 18

Binary file (129802 bytes)

Download a202609288-kexhibit991012.jpg

GRAPHIC

Filename: a202609288-kexhibit991013.jpg · Sequence: 19

Binary file (116289 bytes)

Download a202609288-kexhibit991013.jpg

GRAPHIC

Filename: a202609288-kexhibit991014.jpg · Sequence: 20

Binary file (103340 bytes)

Download a202609288-kexhibit991014.jpg

GRAPHIC

Filename: a202609288-kexhibit991015.jpg · Sequence: 21

Binary file (108400 bytes)

Download a202609288-kexhibit991015.jpg

GRAPHIC

Filename: a202609288-kexhibit991016.jpg · Sequence: 22

Binary file (115897 bytes)

Download a202609288-kexhibit991016.jpg

GRAPHIC

Filename: a202609288-kexhibit991017.jpg · Sequence: 23

Binary file (139117 bytes)

Download a202609288-kexhibit991017.jpg

GRAPHIC

Filename: a202609288-kexhibit991018.jpg · Sequence: 24

Binary file (109905 bytes)

Download a202609288-kexhibit991018.jpg

GRAPHIC

Filename: a202609288-kexhibit991019.jpg · Sequence: 25

Binary file (99637 bytes)

Download a202609288-kexhibit991019.jpg

GRAPHIC

Filename: a202609288-kexhibit991020.jpg · Sequence: 26

Binary file (127296 bytes)

Download a202609288-kexhibit991020.jpg

GRAPHIC

Filename: a202609288-kexhibit991021.jpg · Sequence: 27

Binary file (90362 bytes)

Download a202609288-kexhibit991021.jpg

GRAPHIC

Filename: a202609288-kexhibit991022.jpg · Sequence: 28

Binary file (109274 bytes)

Download a202609288-kexhibit991022.jpg

GRAPHIC

Filename: a202609288-kexhibit991023.jpg · Sequence: 29

Binary file (115510 bytes)

Download a202609288-kexhibit991023.jpg

GRAPHIC

Filename: a202609288-kexhibit991024.jpg · Sequence: 30

Binary file (85656 bytes)

Download a202609288-kexhibit991024.jpg

GRAPHIC

Filename: a202609288-kexhibit991025.jpg · Sequence: 31

Binary file (83501 bytes)

Download a202609288-kexhibit991025.jpg

GRAPHIC

Filename: a202609288-kexhibit991026.jpg · Sequence: 32

Binary file (94088 bytes)

Download a202609288-kexhibit991026.jpg

GRAPHIC

Filename: a202609288-kexhibit991027.jpg · Sequence: 33

Binary file (72010 bytes)

Download a202609288-kexhibit991027.jpg

GRAPHIC

Filename: a202609288-kexhibit991028.jpg · Sequence: 34

Binary file (80450 bytes)

Download a202609288-kexhibit991028.jpg

GRAPHIC

Filename: a202609288-kexhibit991029.jpg · Sequence: 35

Binary file (133324 bytes)

Download a202609288-kexhibit991029.jpg

GRAPHIC

Filename: a202609288-kexhibit991030.jpg · Sequence: 36

Binary file (70720 bytes)

Download a202609288-kexhibit991030.jpg

GRAPHIC

Filename: a202609288-kexhibit992001.jpg · Sequence: 37

Binary file (121495 bytes)

Download a202609288-kexhibit992001.jpg

GRAPHIC

Filename: a202609288-kexhibit992002.jpg · Sequence: 38

Binary file (281958 bytes)

Download a202609288-kexhibit992002.jpg

GRAPHIC

Filename: a202609288-kexhibit992003.jpg · Sequence: 39

Binary file (165847 bytes)

Download a202609288-kexhibit992003.jpg

GRAPHIC

Filename: a202609288-kexhibit992004.jpg · Sequence: 40

Binary file (117803 bytes)

Download a202609288-kexhibit992004.jpg

GRAPHIC

Filename: a202609288-kexhibit992005.jpg · Sequence: 41

Binary file (126619 bytes)

Download a202609288-kexhibit992005.jpg

GRAPHIC

Filename: a202609288-kexhibit992006.jpg · Sequence: 42

Binary file (112119 bytes)

Download a202609288-kexhibit992006.jpg

GRAPHIC

Filename: a202609288-kexhibit992007.jpg · Sequence: 43

Binary file (155979 bytes)

Download a202609288-kexhibit992007.jpg

GRAPHIC

Filename: a202609288-kexhibit992008.jpg · Sequence: 44

Binary file (107183 bytes)

Download a202609288-kexhibit992008.jpg

GRAPHIC

Filename: a202609288-kexhibit992009.jpg · Sequence: 45

Binary file (129670 bytes)

Download a202609288-kexhibit992009.jpg

GRAPHIC

Filename: a202609288-kexhibit992010.jpg · Sequence: 46

Binary file (118199 bytes)

Download a202609288-kexhibit992010.jpg

GRAPHIC

Filename: a202609288-kexhibit992011.jpg · Sequence: 47

Binary file (127410 bytes)

Download a202609288-kexhibit992011.jpg

GRAPHIC

Filename: a202609288-kexhibit992012.jpg · Sequence: 48

Binary file (117374 bytes)

Download a202609288-kexhibit992012.jpg

GRAPHIC

Filename: a202609288-kexhibit992013.jpg · Sequence: 49

Binary file (142301 bytes)

Download a202609288-kexhibit992013.jpg

GRAPHIC

Filename: a202609288-kexhibit992014.jpg · Sequence: 50

Binary file (117618 bytes)

Download a202609288-kexhibit992014.jpg

GRAPHIC

Filename: a202609288-kexhibit992015.jpg · Sequence: 51

Binary file (111821 bytes)

Download a202609288-kexhibit992015.jpg

GRAPHIC

Filename: a202609288-kexhibit992016.jpg · Sequence: 52

Binary file (111003 bytes)

Download a202609288-kexhibit992016.jpg

GRAPHIC

Filename: a202609288-kexhibit992017.jpg · Sequence: 53

Binary file (116051 bytes)

Download a202609288-kexhibit992017.jpg

GRAPHIC

Filename: a202609288-kexhibit992018.jpg · Sequence: 54

Binary file (109854 bytes)

Download a202609288-kexhibit992018.jpg

GRAPHIC

Filename: a202609288-kexhibit992019.jpg · Sequence: 55

Binary file (99510 bytes)

Download a202609288-kexhibit992019.jpg

GRAPHIC

Filename: a202609288-kexhibit992020.jpg · Sequence: 56

Binary file (127490 bytes)

Download a202609288-kexhibit992020.jpg

GRAPHIC

Filename: a202609288-kexhibit992021.jpg · Sequence: 57

Binary file (90395 bytes)

Download a202609288-kexhibit992021.jpg

GRAPHIC

Filename: a202609288-kexhibit992022.jpg · Sequence: 58

Binary file (109152 bytes)

Download a202609288-kexhibit992022.jpg

GRAPHIC

Filename: a202609288-kexhibit992023.jpg · Sequence: 59

Binary file (115484 bytes)

Download a202609288-kexhibit992023.jpg

GRAPHIC

Filename: a202609288-kexhibit992024.jpg · Sequence: 60

Binary file (85635 bytes)

Download a202609288-kexhibit992024.jpg

GRAPHIC

Filename: a202609288-kexhibit992025.jpg · Sequence: 61

Binary file (109723 bytes)

Download a202609288-kexhibit992025.jpg

GRAPHIC

Filename: a202609288-kexhibit992026.jpg · Sequence: 62

Binary file (133901 bytes)

Download a202609288-kexhibit992026.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 64

v3.26.3

Cover

Sep. 28, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Sep. 28, 2026

Registrant Name

CAMP4 THERAPEUTICS CORPORATION

Entity Incorporation, State or Country Code

Entity File Number

001-42365

Entity Tax Identification Number

81-1152476

Entity Address, State or Province

Entity Address, City or Town

Watertown

Entity Address, Address Line Two

Suite 201

Entity Address, Address Line One

100 Talcott Avenue

Entity Address, Postal Zip Code

02472

City Area Code

617

Local Phone Number

651-8867

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

CAMP

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

Central Index Key

0001736730

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration